Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
3D cell-based biosensors in drug discovery programs : microtissue engineering for high throughput screening / / William S. Kisaalita
| 3D cell-based biosensors in drug discovery programs : microtissue engineering for high throughput screening / / William S. Kisaalita |
| Autore | Kisaalita William Ssempa <1953, > |
| Pubbl/distr/stampa | Boca Raton [Fla.] : , : CRC Press, , 2010 |
| Descrizione fisica | 1 online resource (392 p.) |
| Disciplina | 615/.19 |
| Soggetto topico |
Pharmaceutical biotechnology
Biosensors High throughput screening (Drug development) |
| Soggetto genere / forma | Electronic books. |
| ISBN |
0-429-14677-9
1-4200-7350-8 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Front Cover; Dedication; Contents; Preface; Author; Part I. Introduction; Chapter 1. Biosensors and Bioassays; Chapter 2. Target-Driven Drug Discovery; Part II. 3D versus 2D Cultures; Chapter 3. Comparative Transcriptional Profiling and Proteomics; Chapter 4. Comparative Structure and Function; Part III. Emerging Design Principles; Chapter 5. Chemical Microenvironmental Factors; Chapter 6. Spatial and Temporal Microenvironmental Factors; Chapter 7. Material Physical Property and Force Microenvironmental Factors; Chapter 8. Proteomics as a Promising Tool in the Search for 3D Biomarkers
Chapter 9. Readout Present and Near FutureChapter 10. Ready-to-Use Commercial 3D Plates; Part IV. Technology Deployment Challenges and Opportunities; Chapter 11. Challenges to Adopting 3D Cultures in HTS Programs; Chapter 12. Cases for 3D Cultures in Drug Discovery; Chapter 13. Ideal Case Study Design; Appendix A: Patents for 3D Scaffolds; Appendix B: Current Drug Targets; Appendix C: Popular Cell Lines in Drug Discovery; Appendix D: Stem Cells in Drug Discovery; Back Cover |
| Record Nr. | UNINA-9910459023403321 |
Kisaalita William Ssempa <1953, >
|
||
| Boca Raton [Fla.] : , : CRC Press, , 2010 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
3D cell-based biosensors in drug discovery programs : microtissue engineering for high throughput screening / / William S. Kisaalita
| 3D cell-based biosensors in drug discovery programs : microtissue engineering for high throughput screening / / William S. Kisaalita |
| Autore | Kisaalita William Ssempa <1953, > |
| Pubbl/distr/stampa | Boca Raton [Fla.] : , : CRC Press, , 2010 |
| Descrizione fisica | 1 online resource (392 p.) |
| Disciplina | 615/.19 |
| Soggetto topico |
Pharmaceutical biotechnology
Biosensors High throughput screening (Drug development) |
| ISBN |
1-4398-5905-1
0-429-14677-9 1-4200-7350-8 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Front Cover; Dedication; Contents; Preface; Author; Part I. Introduction; Chapter 1. Biosensors and Bioassays; Chapter 2. Target-Driven Drug Discovery; Part II. 3D versus 2D Cultures; Chapter 3. Comparative Transcriptional Profiling and Proteomics; Chapter 4. Comparative Structure and Function; Part III. Emerging Design Principles; Chapter 5. Chemical Microenvironmental Factors; Chapter 6. Spatial and Temporal Microenvironmental Factors; Chapter 7. Material Physical Property and Force Microenvironmental Factors; Chapter 8. Proteomics as a Promising Tool in the Search for 3D Biomarkers
Chapter 9. Readout Present and Near FutureChapter 10. Ready-to-Use Commercial 3D Plates; Part IV. Technology Deployment Challenges and Opportunities; Chapter 11. Challenges to Adopting 3D Cultures in HTS Programs; Chapter 12. Cases for 3D Cultures in Drug Discovery; Chapter 13. Ideal Case Study Design; Appendix A: Patents for 3D Scaffolds; Appendix B: Current Drug Targets; Appendix C: Popular Cell Lines in Drug Discovery; Appendix D: Stem Cells in Drug Discovery; Back Cover |
| Record Nr. | UNINA-9910784909603321 |
|
Kisaalita William Ssempa <1953, >
|
||
| Boca Raton [Fla.] : , : CRC Press, , 2010 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
3D cell-based biosensors in drug discovery programs : microtissue engineering for high throughput screening / / William S. Kisaalita
| 3D cell-based biosensors in drug discovery programs : microtissue engineering for high throughput screening / / William S. Kisaalita |
| Autore | Kisaalita William Ssempa <1953, > |
| Pubbl/distr/stampa | Boca Raton [Fla.] : , : CRC Press, , 2010 |
| Descrizione fisica | 1 online resource (392 p.) |
| Disciplina | 615/.19 |
| Soggetto topico |
Pharmaceutical biotechnology
Biosensors High throughput screening (Drug development) |
| ISBN |
1-4398-5905-1
0-429-14677-9 1-4200-7350-8 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Front Cover; Dedication; Contents; Preface; Author; Part I. Introduction; Chapter 1. Biosensors and Bioassays; Chapter 2. Target-Driven Drug Discovery; Part II. 3D versus 2D Cultures; Chapter 3. Comparative Transcriptional Profiling and Proteomics; Chapter 4. Comparative Structure and Function; Part III. Emerging Design Principles; Chapter 5. Chemical Microenvironmental Factors; Chapter 6. Spatial and Temporal Microenvironmental Factors; Chapter 7. Material Physical Property and Force Microenvironmental Factors; Chapter 8. Proteomics as a Promising Tool in the Search for 3D Biomarkers
Chapter 9. Readout Present and Near FutureChapter 10. Ready-to-Use Commercial 3D Plates; Part IV. Technology Deployment Challenges and Opportunities; Chapter 11. Challenges to Adopting 3D Cultures in HTS Programs; Chapter 12. Cases for 3D Cultures in Drug Discovery; Chapter 13. Ideal Case Study Design; Appendix A: Patents for 3D Scaffolds; Appendix B: Current Drug Targets; Appendix C: Popular Cell Lines in Drug Discovery; Appendix D: Stem Cells in Drug Discovery; Back Cover |
| Record Nr. | UNINA-9910799968303321 |
|
Kisaalita William Ssempa <1953, >
|
||
| Boca Raton [Fla.] : , : CRC Press, , 2010 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Absorption and drug development : solubility, permeability, and charge state / / Alex Avdeef
| Absorption and drug development : solubility, permeability, and charge state / / Alex Avdeef |
| Autore | Avdeef Alex |
| Edizione | [2nd ed.] |
| Pubbl/distr/stampa | Hoboken, N.J., : John Wiley & Sons, c2012 |
| Descrizione fisica | 1 online resource (742 p.) |
| Disciplina | 615/.19 |
| Soggetto topico |
Drugs - Design
Drugs - Metabolism Drug development Absorption |
| ISBN |
1-62198-226-2
1-280-58934-5 9786613619174 1-118-28603-0 1-118-28606-5 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Introduction -- Transport model -- pKa determination -- Octanol-water partitioning -- Liposome-water partitioning -- Solubility -- Permeability - Pampa -- Permeability Caco 2/MDCK -- Permeability blood brain barrier. |
| Record Nr. | UNINA-9910141449403321 |
|
Avdeef Alex
|
||
| Hoboken, N.J., : John Wiley & Sons, c2012 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
ADMET for Medicinal Chemists [[electronic resource] ] : A Practical Guide
| ADMET for Medicinal Chemists [[electronic resource] ] : A Practical Guide |
| Autore | Tsaioun Katya |
| Pubbl/distr/stampa | Hoboken, : Wiley, 2012 |
| Descrizione fisica | 1 online resource (524 p.) |
| Disciplina |
615.19
615/.19 |
| Altri autori (Persone) | KatesSteven A |
| Soggetto topico |
Drug Design
Drug Toxicity Drugs - Testing Drugs --Testing --Juvenile literature Pharmaceutical Preparations - chemistry Pharmacokinetics Metabolic Phenomena Drug Discovery Pharmacological Phenomena Natural Science Disciplines Kinetics Chemicals and Drugs Poisoning Biochemical Phenomena Chemistry, Pharmaceutical Substance-Related Disorders Disciplines and Occupations Investigative Techniques Physiological Phenomena Phenomena and Processes Chemical Phenomena Diseases Pharmacology Analytical, Diagnostic and Therapeutic Techniques and Equipment Biological Science Disciplines Chemistry Pharmaceutical Preparations Health & Biological Sciences Pharmacy, Therapeutics, & Pharmacology |
| ISBN |
1-280-59122-6
9786613621054 0-470-91509-9 0-470-91511-0 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
ADMET for Medicinal Chemists: A Practical Guide; CONTENTS; Preface; Contributors; 1 Introduction; 1.1 Introduction; 1.2 Voyage Through The Digestive System; 1.2.1 The Mouth; 1.2.2 The Stomach; 1.2.3 The Small Intestine: Duodenum; 1.2.4 The Small and Large Intestine: Jejunum, Ileum, Colon; 1.2.5 Hepatic-Portal Vein; 1.3 The Liver Metabolism; 1.3.1 CYP450 (CYPs); 1.4 The Kidneys; 1.4.1 Active Tubular Secretion; 1.4.2 Passive Tubular Reabsorption; 1.5 Conclusions; References; 2 In Silico ADME/Tox Predictions; 2.1 Introduction; 2.2 Key Computer Methods for ADME/Tox Predictions
2.2.1 Drug Discovery2.2.2 Applying or Not ADME/Tox Predictions, Divided Opinions; 2.2.3 In Silico ADME/Tox Methods and Modeling Approaches; 2.2.4 Physicochemistry, Pharmacokinetics, Drug-Like and Lead-Like Concepts; 2.2.5 Lipophilicity; 2.2.6 pKa; 2.2.7 Transport Proteins; 2.2.8 Plasma Protein Binding; 2.2.9 Metabolism; 2.2.10 Elimination; 2.2.11 Toxicity; 2.3 Preparation of Compound Collections and Computer Programs, Challenging ADME/Tox Predictions and Statistical Methods; 2.3.1 Preparation of Compound Collections and Computer Programs 2.3.2 Preparing a Compound Collection: Materials and Methods2.3.3 Cleaning and Designing the Compound Collection; 2.3.4 Searching for Similarity; 2.3.5 Generating 3D Structures; 2.4 ADME/Tox Predictions within Pharmaceutics Companies; 2.4.1 Actelion Pharmaceuticals Ltd.; 2.4.2 Bayer; 2.4.3 Bristol-Myers Squibb; 2.4.4 Hoffmann-La Roche Ltd.; 2.4.5 Neurogen Corporation; 2.4.6 Novartis; 2.4.7 Schering AG; 2.4.8 Vertex Pharmaceuticals; 2.5 Challenging ADME/Tox Predictions; 2.5.1 Tolcapone; 2.5.2 Factor V Inhibitors; 2.5.3 CRF-1 Receptor Antagonists; 2.6 Statistical Methods 2.6.1 Principal Component Analysis2.6.2 Partial Least Square; 2.6.3 Support Vector Machine; 2.6.4 Decision Trees; 2.6.5 Neural Networks; 2.7 Conclusions; References; 3 Absorption and Physicochemical Properties of the NCE; 3.1. Introduction; 3.2. Physicochemical Properties; 3.3. Stability; 3.4. Dissolution and Solubility; 3.4.1. Dissolution Rate, Particle Size, and Solubility; 3.4.2. pH and Salts; 3.4.3. In Vivo Solubilization; 3.5. Solid State; References; 4 ADME; 4.1 Introduction; 4.2 Absorption; 4.2.1 Route of Administration; 4.2.2 Factors Determining Oral Bioavailability; 4.3 Distribution 4.3.1 Drug Distribution4.3.2 Volume of Distribution; 4.3.3 Free Drug Concentration; 4.3.4 CNS Penetration; 4.4 Elimination; 4.4.1 Elimination Versus Clearance; 4.4.2 Metabolism Versus Excretion; 4.4.3 Drug-Free Fraction and Clearance; 4.4.4 Lipophilicity and Clearance; 4.4.5 Transporters and Clearance; 4.4.6 Metabolism; 4.4.7 Excretion; 4.5 Drug Interactions; 4.5.1 Absorption-Driven DDI; 4.5.2 Distribution-Driven DDI; 4.5.3 Excretion-Driven DDI; 4.5.4 Metabolism-Driven DDI; 4.5.5 Tools for Studying Drug Metabolism; 4.5.6 Applications of Drug Metabolism Tools 4.5.7 Tools for Studying Drug Excretion |
| Record Nr. | UNINA-9910133588303321 |
|
Tsaioun Katya
|
||
| Hoboken, : Wiley, 2012 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
ADMET for Medicinal Chemists [[electronic resource] ] : A Practical Guide
| ADMET for Medicinal Chemists [[electronic resource] ] : A Practical Guide |
| Autore | Tsaioun Katya |
| Pubbl/distr/stampa | Hoboken, : Wiley, 2012 |
| Descrizione fisica | 1 online resource (524 p.) |
| Disciplina |
615.19
615/.19 |
| Altri autori (Persone) | KatesSteven A |
| Soggetto topico |
Drug Design
Drug Toxicity Drugs - Testing Drugs --Testing --Juvenile literature Pharmaceutical Preparations - chemistry Pharmacokinetics Metabolic Phenomena Drug Discovery Pharmacological Phenomena Natural Science Disciplines Kinetics Chemicals and Drugs Poisoning Biochemical Phenomena Chemistry, Pharmaceutical Substance-Related Disorders Disciplines and Occupations Investigative Techniques Physiological Phenomena Phenomena and Processes Chemical Phenomena Diseases Pharmacology Analytical, Diagnostic and Therapeutic Techniques and Equipment Biological Science Disciplines Chemistry Pharmaceutical Preparations Health & Biological Sciences Pharmacy, Therapeutics, & Pharmacology |
| ISBN |
1-280-59122-6
9786613621054 0-470-91509-9 0-470-91511-0 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
ADMET for Medicinal Chemists: A Practical Guide; CONTENTS; Preface; Contributors; 1 Introduction; 1.1 Introduction; 1.2 Voyage Through The Digestive System; 1.2.1 The Mouth; 1.2.2 The Stomach; 1.2.3 The Small Intestine: Duodenum; 1.2.4 The Small and Large Intestine: Jejunum, Ileum, Colon; 1.2.5 Hepatic-Portal Vein; 1.3 The Liver Metabolism; 1.3.1 CYP450 (CYPs); 1.4 The Kidneys; 1.4.1 Active Tubular Secretion; 1.4.2 Passive Tubular Reabsorption; 1.5 Conclusions; References; 2 In Silico ADME/Tox Predictions; 2.1 Introduction; 2.2 Key Computer Methods for ADME/Tox Predictions
2.2.1 Drug Discovery2.2.2 Applying or Not ADME/Tox Predictions, Divided Opinions; 2.2.3 In Silico ADME/Tox Methods and Modeling Approaches; 2.2.4 Physicochemistry, Pharmacokinetics, Drug-Like and Lead-Like Concepts; 2.2.5 Lipophilicity; 2.2.6 pKa; 2.2.7 Transport Proteins; 2.2.8 Plasma Protein Binding; 2.2.9 Metabolism; 2.2.10 Elimination; 2.2.11 Toxicity; 2.3 Preparation of Compound Collections and Computer Programs, Challenging ADME/Tox Predictions and Statistical Methods; 2.3.1 Preparation of Compound Collections and Computer Programs 2.3.2 Preparing a Compound Collection: Materials and Methods2.3.3 Cleaning and Designing the Compound Collection; 2.3.4 Searching for Similarity; 2.3.5 Generating 3D Structures; 2.4 ADME/Tox Predictions within Pharmaceutics Companies; 2.4.1 Actelion Pharmaceuticals Ltd.; 2.4.2 Bayer; 2.4.3 Bristol-Myers Squibb; 2.4.4 Hoffmann-La Roche Ltd.; 2.4.5 Neurogen Corporation; 2.4.6 Novartis; 2.4.7 Schering AG; 2.4.8 Vertex Pharmaceuticals; 2.5 Challenging ADME/Tox Predictions; 2.5.1 Tolcapone; 2.5.2 Factor V Inhibitors; 2.5.3 CRF-1 Receptor Antagonists; 2.6 Statistical Methods 2.6.1 Principal Component Analysis2.6.2 Partial Least Square; 2.6.3 Support Vector Machine; 2.6.4 Decision Trees; 2.6.5 Neural Networks; 2.7 Conclusions; References; 3 Absorption and Physicochemical Properties of the NCE; 3.1. Introduction; 3.2. Physicochemical Properties; 3.3. Stability; 3.4. Dissolution and Solubility; 3.4.1. Dissolution Rate, Particle Size, and Solubility; 3.4.2. pH and Salts; 3.4.3. In Vivo Solubilization; 3.5. Solid State; References; 4 ADME; 4.1 Introduction; 4.2 Absorption; 4.2.1 Route of Administration; 4.2.2 Factors Determining Oral Bioavailability; 4.3 Distribution 4.3.1 Drug Distribution4.3.2 Volume of Distribution; 4.3.3 Free Drug Concentration; 4.3.4 CNS Penetration; 4.4 Elimination; 4.4.1 Elimination Versus Clearance; 4.4.2 Metabolism Versus Excretion; 4.4.3 Drug-Free Fraction and Clearance; 4.4.4 Lipophilicity and Clearance; 4.4.5 Transporters and Clearance; 4.4.6 Metabolism; 4.4.7 Excretion; 4.5 Drug Interactions; 4.5.1 Absorption-Driven DDI; 4.5.2 Distribution-Driven DDI; 4.5.3 Excretion-Driven DDI; 4.5.4 Metabolism-Driven DDI; 4.5.5 Tools for Studying Drug Metabolism; 4.5.6 Applications of Drug Metabolism Tools 4.5.7 Tools for Studying Drug Excretion |
| Record Nr. | UNINA-9910830164603321 |
|
Tsaioun Katya
|
||
| Hoboken, : Wiley, 2012 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
ADMET for medicinal chemists : a practical guide / / edited by Katya Tsaioun, Steven A. Kates
| ADMET for medicinal chemists : a practical guide / / edited by Katya Tsaioun, Steven A. Kates |
| Pubbl/distr/stampa | Hoboken, N.J., : John Wiley & Sons, c2011 |
| Descrizione fisica | 1 online resource (524 p.) |
| Disciplina |
615.19
615/.19 |
| Altri autori (Persone) |
KatesSteven A. <1961->
TsaiounKatya |
| Soggetto topico |
Drugs - Testing
Drugs - Design |
| ISBN |
1-280-59122-6
9786613621054 0-470-91509-9 0-470-91511-0 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
ADMET for Medicinal Chemists: A Practical Guide; CONTENTS; Preface; Contributors; 1 Introduction; 1.1 Introduction; 1.2 Voyage Through The Digestive System; 1.2.1 The Mouth; 1.2.2 The Stomach; 1.2.3 The Small Intestine: Duodenum; 1.2.4 The Small and Large Intestine: Jejunum, Ileum, Colon; 1.2.5 Hepatic-Portal Vein; 1.3 The Liver Metabolism; 1.3.1 CYP450 (CYPs); 1.4 The Kidneys; 1.4.1 Active Tubular Secretion; 1.4.2 Passive Tubular Reabsorption; 1.5 Conclusions; References; 2 In Silico ADME/Tox Predictions; 2.1 Introduction; 2.2 Key Computer Methods for ADME/Tox Predictions
2.2.1 Drug Discovery2.2.2 Applying or Not ADME/Tox Predictions, Divided Opinions; 2.2.3 In Silico ADME/Tox Methods and Modeling Approaches; 2.2.4 Physicochemistry, Pharmacokinetics, Drug-Like and Lead-Like Concepts; 2.2.5 Lipophilicity; 2.2.6 pKa; 2.2.7 Transport Proteins; 2.2.8 Plasma Protein Binding; 2.2.9 Metabolism; 2.2.10 Elimination; 2.2.11 Toxicity; 2.3 Preparation of Compound Collections and Computer Programs, Challenging ADME/Tox Predictions and Statistical Methods; 2.3.1 Preparation of Compound Collections and Computer Programs 2.3.2 Preparing a Compound Collection: Materials and Methods2.3.3 Cleaning and Designing the Compound Collection; 2.3.4 Searching for Similarity; 2.3.5 Generating 3D Structures; 2.4 ADME/Tox Predictions within Pharmaceutics Companies; 2.4.1 Actelion Pharmaceuticals Ltd.; 2.4.2 Bayer; 2.4.3 Bristol-Myers Squibb; 2.4.4 Hoffmann-La Roche Ltd.; 2.4.5 Neurogen Corporation; 2.4.6 Novartis; 2.4.7 Schering AG; 2.4.8 Vertex Pharmaceuticals; 2.5 Challenging ADME/Tox Predictions; 2.5.1 Tolcapone; 2.5.2 Factor V Inhibitors; 2.5.3 CRF-1 Receptor Antagonists; 2.6 Statistical Methods 2.6.1 Principal Component Analysis2.6.2 Partial Least Square; 2.6.3 Support Vector Machine; 2.6.4 Decision Trees; 2.6.5 Neural Networks; 2.7 Conclusions; References; 3 Absorption and Physicochemical Properties of the NCE; 3.1. Introduction; 3.2. Physicochemical Properties; 3.3. Stability; 3.4. Dissolution and Solubility; 3.4.1. Dissolution Rate, Particle Size, and Solubility; 3.4.2. pH and Salts; 3.4.3. In Vivo Solubilization; 3.5. Solid State; References; 4 ADME; 4.1 Introduction; 4.2 Absorption; 4.2.1 Route of Administration; 4.2.2 Factors Determining Oral Bioavailability; 4.3 Distribution 4.3.1 Drug Distribution4.3.2 Volume of Distribution; 4.3.3 Free Drug Concentration; 4.3.4 CNS Penetration; 4.4 Elimination; 4.4.1 Elimination Versus Clearance; 4.4.2 Metabolism Versus Excretion; 4.4.3 Drug-Free Fraction and Clearance; 4.4.4 Lipophilicity and Clearance; 4.4.5 Transporters and Clearance; 4.4.6 Metabolism; 4.4.7 Excretion; 4.5 Drug Interactions; 4.5.1 Absorption-Driven DDI; 4.5.2 Distribution-Driven DDI; 4.5.3 Excretion-Driven DDI; 4.5.4 Metabolism-Driven DDI; 4.5.5 Tools for Studying Drug Metabolism; 4.5.6 Applications of Drug Metabolism Tools 4.5.7 Tools for Studying Drug Excretion |
| Altri titoli varianti | Absorption, distribution, metabolism, excretion, toxicity for medical chemists |
| Record Nr. | UNINA-9910876861103321 |
| Hoboken, N.J., : John Wiley & Sons, c2011 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Advances in cancer drug targets [[electronic resource] ] . Volume 1 / / editor, Atta-ur-Rahman
| Advances in cancer drug targets [[electronic resource] ] . Volume 1 / / editor, Atta-ur-Rahman |
| Pubbl/distr/stampa | Sharjah, United Arab Emirates ; ; Oak Park, Ill., : Bentham Science Publishers, [2013?] |
| Descrizione fisica | 1 online resource (316 p.) |
| Disciplina | 615/.19 |
| Altri autori (Persone) | RahmanAtta-ur- <1942-> |
| Collana | Advances in cancer drug targets |
| Soggetto topico |
Cancer - Chemotherapy
Drug targeting |
| Soggetto genere / forma | Electronic books. |
| ISBN | 1-60805-474-8 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Title; EUL; Contents; Foreword; List of Contributors; Chapter 01; Chapter 02; Chapter 03; Chapter 04; Chapter 05; Chapter 06; Chapter 07; Chapter 08; Index |
| Record Nr. | UNINA-9910452673003321 |
| Sharjah, United Arab Emirates ; ; Oak Park, Ill., : Bentham Science Publishers, [2013?] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Advances in cancer drug targets [[electronic resource] ] . Volume 1 / / editor, Atta-ur-Rahman
| Advances in cancer drug targets [[electronic resource] ] . Volume 1 / / editor, Atta-ur-Rahman |
| Pubbl/distr/stampa | Sharjah, United Arab Emirates ; ; Oak Park, Ill., : Bentham Science Publishers, [2013?] |
| Descrizione fisica | 1 online resource (316 p.) |
| Disciplina | 615/.19 |
| Altri autori (Persone) | RahmanAtta-ur- <1942-> |
| Collana | Advances in cancer drug targets |
| Soggetto topico |
Cancer - Chemotherapy
Drug targeting |
| ISBN | 1-60805-474-8 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Title; EUL; Contents; Foreword; List of Contributors; Chapter 01; Chapter 02; Chapter 03; Chapter 04; Chapter 05; Chapter 06; Chapter 07; Chapter 08; Index |
| Record Nr. | UNINA-9910779510903321 |
| Sharjah, United Arab Emirates ; ; Oak Park, Ill., : Bentham Science Publishers, [2013?] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
The agile approach to adaptive research [[electronic resource] ] : optimizing efficiency in clinical development / / Michael J. Rosenberg
| The agile approach to adaptive research [[electronic resource] ] : optimizing efficiency in clinical development / / Michael J. Rosenberg |
| Autore | Rosenberg Michael J |
| Pubbl/distr/stampa | Hoboken, N.J., : Wiley, c2010 |
| Descrizione fisica | 1 online resource (296 p.) |
| Disciplina | 615/.19 |
| Collana | Wiley series on technologies for the pharmaceutical industry |
| Soggetto topico |
Drug development
Pharmaceutical industry |
| ISBN |
1-282-54764-X
9786612547645 0-470-59968-5 0-470-59967-7 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
The Agile Approach to Adaptive Research: Optimizing Efficiency in Clinical Development; Contents; Preface; Acknowledgments; 1 Opportunity for Efficiency; The Adaptive Solution; An Industrial Success Story; Signs of Trouble Ahead; Converging Challenges; The Struggle to Replace Lost Revenues; Clinical Research Is the Key; Behind the High Costs of Clinical Development; High Costs and Increasing Prices; Growing Pressures Mandate Greater Efficiency; The High Risk of Current Development Practices; Economic Consequences of Faster Clinical Development; Thriving in a New Era; References
2 Defining and Extending the Adaptive ApproachThe Adaptive Concept; Knowledge, Time, and Decision Making; The Value of Early Knowledge; The Spectrum of Design and Operational Adaptations; Maximizing the Adaptive Approach: Agile Clinical Development; Measure Performance in Real Time; Metrics in Action; Right Information to the Right Eyes at the Right Time; Make Timely Decisions; Organize Work in Lean Processes; Rework in Clinical Studies; Backflow of Patient Data; Match Technology with Tasks; Objections to Adaptive Methods; Integrity and Validity; The Regulatory Environment The Complexity of Clinical ResearchConclusion; References; 3 Design Adaptations Part One: Finding the Right Dose; Background; Types of Design Adaptations; Order of Discussion; Dosing Nomenclature; Determining Maximum Safe Dose; Single Arm; Continual Reassessment Method; Other Bayesian Dose-Finding Methods; Determining Optimal Dose (Pruning); Multiple Arms; Improvements over Conventional Approaches to Dose Finding; Dose Selection in Practice; Optimizing Dose Selection; Minimizing Costs Versus Maximizing Information; Surrogate Endpoints; Conclusion; References 4 Design Adaptations Part Two: Additional Design ChangesSample-Size Reestimation; The Trouble with Planning Estimates; The High Cost of "Underbuilt" Studies; The Benefits of Reestimation and Rightsizing; Reestimation and Trial Stages; Rules to Restrict Reestimation; Adjusting Sample Size for Nuisance Parameters; Seamless Designs: Combining Multiple Phases; When to Consider Seamless Studies; Seamless Phase I/Phase II Trials; Seamless Phase II/Phase III Trials; Planning Issues in Seamless Trials; Phase I-II-III Designs; Adaptive Randomization; Response-Adaptive Randomization Other Forms of Adaptive RandomizationOther Types of Design Adaptations; Noninferiority-to-Superiority Design; Adaptive Hypotheses and Subpopulations; Treatment Switching; Conclusions; References; 5 Operational Adaptations; Design and Operational Adaptations; The Nature and Significance of Operational Adaptations; Implementing Operational Adaptations; Enrollment and Other Site Issues; Data Quality; Monitoring; Site Closeout and Database Lock; Supporting Functions for Efficient Operations; The Bottom Line; References; 6 Agile Clinical Development; Benefits of Agile Development A Development Example |
| Record Nr. | UNINA-9910140620203321 |
|
Rosenberg Michael J
|
||
| Hoboken, N.J., : Wiley, c2010 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
